Bogdan Anamaria, Manera Valeria, Koenig Alexandra, David Renaud
Centre Hospitalier Universitaire de Nice, Centre Mémoire de Ressources et de Recherche, Nice, France.
CoBTeK Lab "Cognition Behaviour Technology", University of Nice Sophia Antipolis, Nice, France.
Front Pharmacol. 2020 Jan 23;10:1581. doi: 10.3389/fphar.2019.01581. eCollection 2019.
Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.
冷漠是许多神经退行性疾病中最常见的行为障碍之一，已知其会对疾病进展产生负面影响，尤其是在阿尔茨海默病中。目前治疗选择有限，非药物方法应作为一线治疗。缺乏可能降低冷漠水平的药物。本文的目的是综述神经退行性疾病中冷漠的近期药物治疗。检索了Pubmed数据库，特别关注截至2017年1月发表的文章。尽管有一些相互矛盾的结果，但目前已有关于胆碱能、谷氨酸能和多巴胺能药物降低冷漠水平的主要证据水平的报道。然而，治疗持续时间和样本量可能降低了先前结果的有效性。涉及更多参与者/治疗持续时间或不同神经通路的正在进行的研究可能会为神经退行性疾病中冷漠的治疗提供新的见解。
